Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults

• Published in: Cochrane database of systematic reviews 2014-11, Vol.2014 (11), p.CD007403
• Main Authors: Derry, Sheena, Matthews, Paul R L, Wiffen, Philip J, Moore, R Andrew
• Format: Article
• Language: English
• Subjects: Acute Disease; Acute pain; Administration, Topical; Adult; Chronic Disease; Chronic non‐cancer pain; Humans; Irritants - administration & dosage; Irritants - adverse effects; Musculoskeletal Pain - drug therapy; Orthopaedics & trauma; Pain & anaesthesia; Randomized Controlled Trials as Topic; Salicylates - administration & dosage; Salicylates - adverse effects
• ISSN: 1469-493X
• DOI: 10.1002/14651858.CD007403.pub3

Rubefacients containing salicylates cause irritation of the skin and are believed to relieve various musculoskeletal pains. They are available on prescription, and are common components in over-the-counter remedies. This is an update of a review of rubefacients for acute and chronic pain, originally published in 2009, which found limited evidence for efficacy. To assess the efficacy and safety of topically applied salicylates in acute and chronic musculoskeletal pain in adults. We searched CENTRAL, MEDLINE, and EMBASE, from inception to 22 August 2014, together with the Oxford Pain Relief Database, two clinical trial registries, and the reference lists of included studies and relevant reviews. Randomised, double-blind, placebo- or active-controlled clinical trials of topical rubefacients containing salicylates to treat musculoskeletal pain in adults, with at least 10 participants per treatment arm, and reporting outcomes at close to 7 (minimum 3, maximum 10) days for acute conditions and 14 (minimum 7) days or longer for chronic conditions. Two review authors independently assessed trials for inclusion and risk of bias, and extracted data. We calculated risk ratio (RR) and number needed to treat to benefit or harm (NNT or NNH) with 95% confidence intervals (CI) using a fixed-effect model. We analysed acute and chronic conditions separately. New searches for this update identified one new study that satisfied our inclusion criteria, although it contributed information only for withdrawals. Six placebo- and one active-controlled studies (560 and 137 participants, respectively) in acute pain, and seven placebo- and three active-controlled studies (489 and 182 participants, respectively) in chronic pain were included in the review. All studies were potentially at risk of bias, and there were substantial differences between studies in terms of the participants (for example the level of baseline pain), the treatments (different salicylates combined with various other potentially active ingredients), and the methods (for example the outcomes reported). Not all of the studies contributed usable information for all of the outcomes sought.For the primary outcome of clinical success at seven days in acute conditions (mostly sprains, strains, and acute low back pain), the RR was 1.9 (95% CI 1.5 to 2.5) and the NNT was 3.2 (2.4 to 4.9) for salicylates compared with placebo, but this result was not robust (very low quality evidence). Using a random-effects model for ana